 |
|
| Blog results | Results 1 - 10 of about 1,984 for raloxifene breast cancer prevention. (0.33 seconds) |
| Sorted by relevance Sort by date |
| 13 Nov 2009 by Margaret Polaneczky, MD (aka TBTAM) So let's talk about tamoxifen and raloxifene, two drugs that are approved for the prevention of breast cancer. Tamoxifen and Raloxifene. The maker of Evista (raloxifene) is targeting both docs and women, urging them to calculate their ... The Blog that Ate Manhattan - http://theblogthatatemanhattan.blogspot.com/ - References |
| 18 Nov 2009 Then, in 1999, he had a chance to do another breast cancer prevention trial, this time of an osteoporosis drug, raloxifene, or Evista, which did not have the cancer drug taint. It was to be compared with tamoxifen. ... Mike the Mad Biologist - http://scienceblogs.com/mikethemadbiologist/ - References |
| 16 Nov 2009 by David Gorski And as for your endorsement of tamoxifen and raloxifene for breast cancer prevention, while there's no doubt it is beneficial for women at high-risk, there's no effort to in her story or your post to compare the benefits of those drugs ... Science-Based Medicine - http://www.sciencebasedmedicine.org/ - References |
| 17 Nov 2009 The comparative effectiveness review found that all three drugs — tamoxifen, raloxifene, and tibolone — significantly reduce invasive breast cancer in midlife and older women who have not previously had breast cancer, but that benefits ... Nurse.com News - http://www.nurse.com/ |
| 13 Nov 2009 by Sitemaster Specifically, the article discusses the widespread disinterest in the use of finasteride and dutasteride even by patients at significant risk for prostate cancer and in the use of raloxifene and tamoxifen for the prevention of breast ... THE "NEW" PROSTATE CANCER INFOLINK - http://prostatecancerinfolink.net/ - References |
| 10 Nov 2009 by VeZİRH@N In the prophylactic setting, the necessity of finding an agent with as few detrimental side effects as possible combined with as many potential added benefits as possible without sacrificing breast cancer prevention efficacy are all of ... Untitled - http://www.birdunyabilgi.net/ |
| 29 Oct 2009 by Legault, Maki, Resnick, Coker, Hogan, Bevers,... Conclusion Tamoxifen and raloxifene are associated with similar patterns of cognitive function in postmenopausal women at increased risk of breast cancer. Future comparisons between these findings and patterns of cognitive function in ... Journal of Clinical Oncology Current Issue - http://jco.ascopubs.org/ [ More results from Journal of Clinical Oncology Current Issue ] |
| 16 Nov 2009 A $110 million clinical trial showed that its ability to prevent breast cancer is not statistically significantly different than that of tamoxifen, with the advantage that, unlike tamoxifen, raloxifene does not increase the risk of ... Respectful Insolence - http://scienceblogs.com/insolence/ - References |
| 16 Nov 2009 by Crabby McSlacker Likewise, according to the Times, studies have found that taking tamoxifen or raloxifene could cut breast cancer by 50% among high-risk women. Most side effects of the drugs were minor and temporary. There was a very slightly increased risk of ... Well, the Times interviewed Dr. Therese B. Bevers, a medical director at a Cancer Prevention Center. She believes that doctors don't want to take the first step — calculating a woman's lifetime risk of getting breast cancer. ... Cranky Fitness - http://www.crankyfitness.com/ - References |
| 10 Nov 2009 by NHS Choices Raloxifene is more selective in its effects, blocking oestrogen receptors in some tissues but not others. Raloxifene is used in the treatment of osteoporosis and has been trialled for the prevention of breast cancer in humans. ... Health News from NHS Choices - http://www.nhs.uk/News/Pages/NewsArticles.aspx - References |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
